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Background: We present the potential of inclusion bodies (IBs) as a protein delivery method for polymeric
filamentous proteins. We used as cell factory a strain of E. coli, a conventional host organism, and keratin 14 (K14) as
an example of a complex protein. Keratins build the intermediate filament cytoskeleton of all epithelial cells. In
order to build filaments, monomeric K14 needs first to dimerize with its binding partner (keratin 5, K5), which is
then followed by heterodimer assembly into filaments.
Results: K14 IBs were electroporated into SW13 cells grown in culture together with a “reporter” plasmid
containing EYFP labeled keratin 5 (K5) cDNA. As SW13 cells do not normally express keratins, and keratin filaments
are built exclusively of keratin heterodimers (i.e. K5/K14), the short filamentous structures we obtained in this study
can only be the result of: a) if both IBs and plasmid DNA are transfected simultaneously into the cell(s); b) once
inside the cells, K14 protein is being released from IBs; c) released K14 is functional, able to form heterodimers with
EYFP-K5.
Conclusions: Soluble IBs may be also developed for complex cytoskeletal proteins and used as nanoparticles for
their delivery into epithelial cells.
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When expressing recombinant proteins in bacteria, one
of the most common side effects is the formation of
inclusion bodies (IBs) [1]. Until recently IBs were
thought of as blocks of misfolded and inactive proteins.
As it was difficult and expensive to purify and refold
recombinant proteins from such aggregates, a whole
range of strategies was adopted to reduce or avoid IB
formation. Surprisingly, although there was published
evidence that inclusion bodies can also contain biologi-
cally active proteins [2,3], it was not until recently that
this phenomenon was fully acknowledged and further
investigated [4,5]. Many different protocols for IB pro-
duction have been published, focusing on the various
parameters that can affect IB quality such as the genetic
background of the host organism, specific growth condi-
tions and IB isolation [6-18]. Furthermore, the term
“non-classical” inclusion bodies (ncIBs) was introduced* Correspondence: mirjana.liovic@mf.uni-lj.si or mirjana.liovic@ki.si
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reproduction in any medium, provided the orto describe IBs containing a significant amount of pro-
perly folded protein, which in addition could be
extracted under non-denaturing conditions. Although
the major factor in obtaining soluble IBs is the target
protein’s structure, the type of host organism used and
the design of the biosynthesis process may also modulate
IB size and degree of solubility. The fact that inclusion
bodies may contain biologically active proteins has been
already shown for a number of proteins, from GFP
[4,16,17], to recombinant cytokines such as granulocyte
colony-stimulating factor [5] and a number of enzymes
[19-23]. Therefore, the development of IBs as a novel
type of recombinant protein delivery machines has great
potential with applications in medicine, and it has been
also recently patented [24].
The aim of this study was to provide evidence that IBs
may be also used as method of recombinant protein
delivery for complex proteins. By using an already pub-
lished protocol for IB production via the E. coli BL21
(DE3) strain [17], we obtained keratin 14 (K14) ncIBs of
several hundred nanometres in size, which were subse-
quently introduced into SW13 epithelial cells grown intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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side the cells a portion of the K14 protein is released
and dimerizes with EYFP labeled K5, resulting in short
filamentous structures, precursors of keratin filaments.
Results and discussion
As shown in Figure 1, the majority of the K14 IBs we
tested in this study were spherical in shape and approxi-
mately 400–500 nm in size. High power magnification
(Figure 1B) proved that they consisted of much smaller
nuclei of accumulated protein, in turn attached to each
other forming a complex higher order structure.
The obtained K14 IBs displayed a significant level of
solubility. Proteins extracted from bacterial cells were
first resolved on a Comassie stained SDS-PAGE gel
(Figure 2A). Lanes 3 and 4 (Figure 2A) correspond to
the soluble and insoluble fractions of extracted K14 IBs,
dissolved in a mild detergent solution (0.2%N-lauroyl-
sarcosine). Figure 2B shows an immunoblot of the same
bacterial cell extracts with an antibody raised against
K14, confirming that the strong band visible after
Comassie staining (approx. 51 kDa, marked with an
arrow) is indeed K14. Furthermore, we demonstrate that
our K14 IBs are partially soluble already in commercially
available cell culture media, such as Epilife serum-free
medium (Invitrogen) (Figure 2C, lane 1), and DMEM
(Figure 2C, lane 2). As the obtained K14 IBs are soluble
under non-denaturing conditions, they may be classified
as non-classical IBs (ncIBs).
To prove that our K14 ncIBs contain functional K14,
we performed a series of electroporation experiments on
SW13 cells (a human adrenal carcinoma cell line). As
SW13 cells do not normally express keratins, and kera-
tins are obligate heterodimers (build heterodimer subu-
nits with a particular keratin partner), both K14 (in theFigure 1 Field emission scanning electron microscopy of K14 inclusio
500 nm. (b) A high power magnification of K14 IBs, scale bar 100 nm.form of ncIBs) and its binding partner, K5 (in the form
of plasmid DNA containing EYFP labelled K5 cDNA),
need to be simultaneously introduced into these cells.
Short K5/K14 fragments (filament precursors) will form
not only if the K14 protein is released out of the K14
ncIBs, but also if it is able to heterodimerize with over-
expressed EYFP-K5 and these subunits are in turn able
to stack up (polymerize) into filament fragments. In
Figure 3 are presented the results of such de novo fila-
ment formation experiments, at the stage of 2 days after
electroporation. Panel (A) is representative of SW13
cells electroporated with a mixture of K14 ncIBs and
EYFP-K5 plasmid DNA. Panel (B) is representative for
the positive control experiment, consisting of cells elec-
troporated with plasmid DNAs encoding for EYFP-K5
and EYFP-K14. To demonstrate that overexpressed
EYFP-K5 on its own does not form any filamentous
structures and only gives rise to background staining, we
also performed a negative control experiment (panel C).
In this case SW13 cells were electroporated only with
the EYFP-K5 plasmid, resulting in a “milky” fluorescent
background. Therefore, the background visible in (A) is
due to EYFP-K5 plasmid DNA overexpression and the
presence of unpolymerized EYFP-K5 protein: the quan-
tity of synthesized protein by plasmid DNA overexpres-
sion is much greater than the amount of soluble K14
protein introduced into cells by means of ncIBs. In panel
(B), monomeric K5 and K14 proteins are produced in
more equimolar amounts due to both EYFP-K5 and
EYFP-K14 plasmid DNAs overexpression, and these are
constantly being used up through K5/K14 dimerization.
Under the presented experimental conditions and in a
keratin-null cell line such as SW13, the rate-limiting fac-
tor for K5/K14 filament formation is the quantity of
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Figure 2 SDS-PAGE gel analysis of K14 inclusion bodies. (A)
Comassie stained SDS-PAGE gel of proteins extracted from bacterial
cell lysates: 1, soluble (cytoplasmic) proteins; 2, IB proteins; 3, IB
proteins extracted with 0.2% NLS; 4, IB proteins insoluble in 0.2%
NLS. (B) Western blot analysis of the same protein extracts as in A,
however imunoblotted against K14: 1, soluble (cytoplasmic) proteins;
2, IB proteins; 3, IB proteins extracted with 0.2% NLS; 4, proteins
insoluble in 0.2% NLS. (C) Western blot analysis of K14 IBs solubilized
over night in 1, Epilife serum-free medium, and 2, DMEM medium.
The arrow points out bands corresponding to K14, which has a
molecular weight of 51 kDa.
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Overall, the results of these two experiments
(Figure 3A with B) are similar, as in both experiments
dot-like particles, larger speckles and short filamentous
structures (see arrows) are visible. Importantly,
although the K14 ncIBs used in these experiments
were not purified in any particular way after extraction
from bacterial cells, no cytotoxic effect was observed
even at longer time points (7 days) after electropor-
ation (data not shown).a b
Figure 3 Epi-fluorescent microscopy of electroporated SW13 cells. (a)
containing EYFP labeled K5 cDNA. (b) The positive control experiment, whe
and EYFP-K14. (C) The negative control experiment, where cells were electr
and (b) resulted in a multitude of speckles and short filamentous structureConclusions
We provide for the first time evidence that a polymeric
cytoskeletal protein may be produced in the form of
inclusion bodies and used in this form to supplement
epithelial cells lacking it. The production is cost effective
(cheap), no particular purification step is needed, as our
ncIBs appear not to be cytotoxic, and with the end result
similar to the effect of a plasmid DNA construct. In this
study electroporation was chosen as method for K14
ncIB delivery because of their size (currently several
hundred nanometers). During electroporation small
hydrophilic pores are transiently formed in the cell
membrane, and this method has been demonstrated to
work well also in in vivo experiments [25-27], particu-
larly on skin. Nevertheless, other approaches may work
as well, especially in the case of delivery of smaller IBs,
which is something that needs to be further investigated.
A choice of a different E. coli strain as cell factory could
help improve the biosynthesis process, however there
have been also reports on the advantages of host organ-
isms such as gram-positive bacteria (Bacillus sp.), yeast
and fungi [28-30], which can circumvent some of the
limitations of E. coli. In fact, the choice of a different
host organism may be the next appropriate step towards
the optimization of this particular ncIB synthesis proto-
col, as a significantly higher proportion of properly
folded protein needs to be delivered in order to achieve
a therapeutic effect. The data presented in this manu-
script is extremely promising, as it indicates that soluble
IBs may be also obtained for cellular proteins that exert
their function by building intricate polymeric structures.
As skin is the most accessible organ by far, this method
may particularly find possible applications in dermatol-
ogy and the cosmetics industry.c
SW13 cells electroporated with a mixture of K14 ncIBs and a plasmid
re cells were electroporated with plasmid DNAs encoding for EYFP-K5
oporated exclusively with EYFP-K5 plasmid DNA. Experiments in (a)
s (see arrows). The scale bar is 20 μm.
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Cell culture, electroporation and microscopy
Human adrenal carcinoma cells (SW13 cell line) were
grown in DMEM (PAA, Austria) supplemented with
10%FBS (PAA, Austria) and an antibiotic-antimicotic re-
agent (cat no 15240–062, Gibco), at 37°C and 5% CO2.
Cells were cultivated in T75 cm2 cell culture flasks until
confluence. Before electroporation, cells were trypsinized
and counted. In each electroporation experiment 5x106
cells were used.
IBs were resuspended in PBS buffer and an aliquot
was subsequently diluted in electroporation buffer. Ap-
proximately 150 μg of K14 IBs and 10 μg of plasmid
DNA (with EYFP-K5) was mixed and electroporated into
SW13 cells using a Gene Pulser (Bio-Rad) electroporator
set at 125 μF capacitance extender, 200 Ω pulse contro-
ler, 25 μF gene pulser capacitance and 1.5 kV voltage. In
the positive control experiment 10 μg of each plasmid
DNA (EYFP-K5 and EYFP-K14) were mixed and electro-
porated under the following Gene-Pulser settings: cap-
acitance extender 125 μF, pulse controler 200 Ω, gene
pulser capacitance 3 μF, voltage 2.5 kV. After electropor-
ation cells were plated out onto 13 mm coverslips and
incubated for a further 24 hrs, 48 hrs, 72 hrs and 7 days.
At each time point cells were fixed with methanol-acet-
one (1:1), immunostained with a primary mouse
monoclonal antibody against K14 (LL001) followed by a
goat-anti-mouse FITC labeled secondary antibody (Alexa
Fluor, Molecular Probes). Coverslips were analyzed on a
Zeiss T200 inverted microscope operated by Zeiss Axio-
vision software and representative images were taken
with a Zeiss Axiocam colour camera.
Keratin constructs and inclusion bodies production
Keratin 14 (KRT14) cDNA sequence was cloned into
pET23b expression plasmid (Novagen) using the Nde I
restriction site. A previously published protocol for IB
production was used [17]. In brief, the E. coli BL21
(DE3) strain (Novagen) was used. Inclusion bodies were
produced in a shake culture flask with GYSP/amp100
medium, at 25°C and 160 rpm, until the culture reached
the stationary phase. At this point bacterial cells were
disrupted using a high-pressure homogenizer Emulsi-
flex-C5 (Avestin) at operating pressure 75–100 MPa.
After cell disruption IBs were washed twice with PBS
buffer and stored for further analysis and applications.
The supernatant (soluble protein fraction) was also
stored for analysis.
Keratin 5 cDNA sequence was cloned into the pEYFP-C1
plasmid (Clontech) using Eco RI and Bam HI restriction sites.
K14 protein extraction from IBs
IBs resuspended in solubilizing buffer (40 mM Tris/HCl
with 0.2%N-lauroyl sarcosine, pH 8.0) were incubated ina shaker for 24 hrs at 20°C, then centrifuged at 4400 g
for 15 minutes. N-lauroyl sarcosine was removed using a
Dovex 1 x 4–50 ion exchange resin (Sigma).
In a parallel experiment IBs were also dissolved in
DMEM after a 24 hrs incubation at 20°C in a shaker.
The soluble and insoluble fractions were separated by
centrifugation at 4400 g for 15 minutes. Samples were
analyzed on 4-12% Nu-PAGE Bis-Tris SDS-PAGE gels
(Invitrogen) and stained with Colloidal Blue (Invitrogen).
Western blot detection was performed using a primary
mouse monoclonal antibody against K14 (LL001) fol-
lowed by a secondary HRP labeled anti-mouse secondary
antibody (Sigma).
Scanning electron microscopy
IBs were thoroughly washed in pure water, mounted on
gold-coated polycarbonate membrane filter with a 0.22
μm pore size (IsoporeTM, Millipore). Samples were ana-
lyzed using a high-resolution Zeiss SUPRA 35 VP field
emission scanning electron microscope.
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